Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer

• Published in: International journal of oncology Vol. 62; no. 3
• Main Authors: Masud, Neshat, Aldahish, Afaf, Iczkowski, Kenneth A, Kale, Ajay, Shah, Girish V
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications UK Ltd 01-03-2023; D.A. Spandidos
• Subjects: Androgens; Autopsies; Biomarkers; Biopsy; Cell culture; Cloning; DNA-Binding Proteins - metabolism; Genes; Histology; Humans; Hybridization; Male; Phosphatidylinositol 3-Kinases - metabolism; Prostate cancer; Prostatic Neoplasms - pathology; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Tumors; Zinc Fingers; Louisiana; United States > US; prostate cancer; cancer marker; neuroendocrine; calcitonin; zinc finger protein like 1
• ISSN: 1019-6439; 1791-2423
• DOI: 10.3892/ijo.2023.5486

Prostate‑derived calcitonin (CT) and its receptor induce tumorigenicity and increase metastatic potential of prostate cancer (PC). CT‑inducible genes in human prostate were identified by subtraction hybridization. Among these genes, zinc finger protein like 1 (ZFPL1) protein was interesting since it was abundantly expressed in malignant prostates but was almost absent in benign prostates. ZFPL1 expression was upregulated by CT and androgens, and ZFPL1 protein was secreted by prostate tumor cells through exosomal secretion. Serum levels of ZFPL1 in cancer patients were at least 4‑fold higher than those in the sera of cancer‑free individuals. Cell biology of ZFPL1 suggests its localization in Golgi bodies and exosomes, and its colocalization with chromogranin A and CD44. These results suggested that ZFPL1 is secreted by tumor cells of neuroendocrine (NE)/stem cell phenotype. The knockdown of endogenous ZFPL1 in (PC) cells led to a remarkable decrease in cell proliferation, and invasion while increasing their apoptosis. As expected, the overexpression of ZFPL1 in prostate cells had an opposite effect on these functions. The knockdown of ZFPL1 in PC cells also decreased Akt phosphorylation, suggesting the actions of ZFPL1 may be mediated through the PI3K‑Akt pathway. Moreover, the present results revealed that ZFPL1 is released by tumors cells of NE or androgen‑independent phenotype and its serum levels are significantly higher in cancer patients, suggesting that it may serve as a blood‑based non‑invasive biomarker of aggressive PC.